Profiling mTOR pathway in neuroendocrine tumors

S. Cingarlini, M. Bonomi, C. Trentin, V. Corbo, A. Scarpa, G. Tortora

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating critical cellular processes such as growth, proliferation, and protein synthesis. The study of cancer predisposing syndromes within which neuroendocrine tumors (NETs) may arise has furnished clues on the involvement of mTOR pathway in sporadic diseases so far. Recent comprehensive analyses have definitely shown activation of mTOR pathway in both experimental and human sporadic NETs. Upstream regulators of mTOR (PTEN and TSC2) have been found mutated in sporadic PNETs. Activation of mTOR pathways in NETs is already demonstrated by expression profiles analysis that revealed downregulation of TSC2 gene and alterations of TSC2 and PTEN protein expression in the vast majority of tumors well-differentiated tumors. Moreover, a global microRNA expression analysis revealed the overexpression, in highly aggressive tumors, of a microRNA (miR-21) that targets PTEN reducing its expression and therefore leading to mTOR activation as well. Overall, these clues have furnished the rationale for the use of mTOR inhibitors the treatment for PNETs. With the recent approval of everolimus (mTOR-targeted drug) for the treatment of advanced PNETs, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR pathway involvement in NETs, the clinical evidence supporting the use of mTOR inhibitors in cancer treatment, and the current clinical issues that remain to be elucidated to improve patients’ management.

Original languageEnglish
Title of host publicationManagement of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach
PublisherSpringer-Verlag Paris
Pages9-27
Number of pages19
ISBN (Electronic)9782817804309
ISBN (Print)9782817804293
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Neuroendocrine Tumors
Sirolimus
Primitive Neuroectodermal Tumors
Neoplasms
MicroRNAs
PTEN Phosphohydrolase
Protein-Serine-Threonine Kinases
Therapeutics
Down-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cingarlini, S., Bonomi, M., Trentin, C., Corbo, V., Scarpa, A., & Tortora, G. (2014). Profiling mTOR pathway in neuroendocrine tumors. In Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach (pp. 9-27). Springer-Verlag Paris. https://doi.org/10.1007/978-2-8178-0430-9_2

Profiling mTOR pathway in neuroendocrine tumors. / Cingarlini, S.; Bonomi, M.; Trentin, C.; Corbo, V.; Scarpa, A.; Tortora, G.

Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach. Springer-Verlag Paris, 2014. p. 9-27.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cingarlini, S, Bonomi, M, Trentin, C, Corbo, V, Scarpa, A & Tortora, G 2014, Profiling mTOR pathway in neuroendocrine tumors. in Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach. Springer-Verlag Paris, pp. 9-27. https://doi.org/10.1007/978-2-8178-0430-9_2
Cingarlini S, Bonomi M, Trentin C, Corbo V, Scarpa A, Tortora G. Profiling mTOR pathway in neuroendocrine tumors. In Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach. Springer-Verlag Paris. 2014. p. 9-27 https://doi.org/10.1007/978-2-8178-0430-9_2
Cingarlini, S. ; Bonomi, M. ; Trentin, C. ; Corbo, V. ; Scarpa, A. ; Tortora, G. / Profiling mTOR pathway in neuroendocrine tumors. Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach. Springer-Verlag Paris, 2014. pp. 9-27
@inbook{d537e35b2543425dba120e852b878ae9,
title = "Profiling mTOR pathway in neuroendocrine tumors",
abstract = "The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating critical cellular processes such as growth, proliferation, and protein synthesis. The study of cancer predisposing syndromes within which neuroendocrine tumors (NETs) may arise has furnished clues on the involvement of mTOR pathway in sporadic diseases so far. Recent comprehensive analyses have definitely shown activation of mTOR pathway in both experimental and human sporadic NETs. Upstream regulators of mTOR (PTEN and TSC2) have been found mutated in sporadic PNETs. Activation of mTOR pathways in NETs is already demonstrated by expression profiles analysis that revealed downregulation of TSC2 gene and alterations of TSC2 and PTEN protein expression in the vast majority of tumors well-differentiated tumors. Moreover, a global microRNA expression analysis revealed the overexpression, in highly aggressive tumors, of a microRNA (miR-21) that targets PTEN reducing its expression and therefore leading to mTOR activation as well. Overall, these clues have furnished the rationale for the use of mTOR inhibitors the treatment for PNETs. With the recent approval of everolimus (mTOR-targeted drug) for the treatment of advanced PNETs, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR pathway involvement in NETs, the clinical evidence supporting the use of mTOR inhibitors in cancer treatment, and the current clinical issues that remain to be elucidated to improve patients’ management.",
author = "S. Cingarlini and M. Bonomi and C. Trentin and V. Corbo and A. Scarpa and G. Tortora",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-2-8178-0430-9_2",
language = "English",
isbn = "9782817804293",
pages = "9--27",
booktitle = "Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach",
publisher = "Springer-Verlag Paris",

}

TY - CHAP

T1 - Profiling mTOR pathway in neuroendocrine tumors

AU - Cingarlini, S.

AU - Bonomi, M.

AU - Trentin, C.

AU - Corbo, V.

AU - Scarpa, A.

AU - Tortora, G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating critical cellular processes such as growth, proliferation, and protein synthesis. The study of cancer predisposing syndromes within which neuroendocrine tumors (NETs) may arise has furnished clues on the involvement of mTOR pathway in sporadic diseases so far. Recent comprehensive analyses have definitely shown activation of mTOR pathway in both experimental and human sporadic NETs. Upstream regulators of mTOR (PTEN and TSC2) have been found mutated in sporadic PNETs. Activation of mTOR pathways in NETs is already demonstrated by expression profiles analysis that revealed downregulation of TSC2 gene and alterations of TSC2 and PTEN protein expression in the vast majority of tumors well-differentiated tumors. Moreover, a global microRNA expression analysis revealed the overexpression, in highly aggressive tumors, of a microRNA (miR-21) that targets PTEN reducing its expression and therefore leading to mTOR activation as well. Overall, these clues have furnished the rationale for the use of mTOR inhibitors the treatment for PNETs. With the recent approval of everolimus (mTOR-targeted drug) for the treatment of advanced PNETs, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR pathway involvement in NETs, the clinical evidence supporting the use of mTOR inhibitors in cancer treatment, and the current clinical issues that remain to be elucidated to improve patients’ management.

AB - The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating critical cellular processes such as growth, proliferation, and protein synthesis. The study of cancer predisposing syndromes within which neuroendocrine tumors (NETs) may arise has furnished clues on the involvement of mTOR pathway in sporadic diseases so far. Recent comprehensive analyses have definitely shown activation of mTOR pathway in both experimental and human sporadic NETs. Upstream regulators of mTOR (PTEN and TSC2) have been found mutated in sporadic PNETs. Activation of mTOR pathways in NETs is already demonstrated by expression profiles analysis that revealed downregulation of TSC2 gene and alterations of TSC2 and PTEN protein expression in the vast majority of tumors well-differentiated tumors. Moreover, a global microRNA expression analysis revealed the overexpression, in highly aggressive tumors, of a microRNA (miR-21) that targets PTEN reducing its expression and therefore leading to mTOR activation as well. Overall, these clues have furnished the rationale for the use of mTOR inhibitors the treatment for PNETs. With the recent approval of everolimus (mTOR-targeted drug) for the treatment of advanced PNETs, this paradigm has been effectively translated into the clinical setting. In this review, we discuss mTOR pathway involvement in NETs, the clinical evidence supporting the use of mTOR inhibitors in cancer treatment, and the current clinical issues that remain to be elucidated to improve patients’ management.

UR - http://www.scopus.com/inward/record.url?scp=84955711886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955711886&partnerID=8YFLogxK

U2 - 10.1007/978-2-8178-0430-9_2

DO - 10.1007/978-2-8178-0430-9_2

M3 - Chapter

AN - SCOPUS:84955711886

SN - 9782817804293

SP - 9

EP - 27

BT - Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach

PB - Springer-Verlag Paris

ER -